Drug Approval | November 22, 2021
Amneal gets approval for Difluprednate ophthalmic emulsion
The company is moving towards complex and more differentiated products
The company is moving towards complex and more differentiated products
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Subscribe To Our Newsletter & Stay Updated
